Overview
PharmaCyte Biotech, Inc., based in the United States, operates within the biotechnology industry, focusing on developing cellular therapies for cancer and diabetes. Utilizing its signature live-cell encapsulation technology, Cell-in-a-Box, the company aims to improve the effectiveness of cancer treatments by encapsulating genetically engineered cells that convert inactive chemotherapy drugs into their active form directly at the tumor site. This innovative approach is primarily directed toward pancreatic cancer, a key project that positions PharmaCyte at the forefront of targeted therapy in oncology. Simultaneously, the company is pursuing the application of its technology in the treatment of insulin-dependent diabetes, aiming to create a bio-artificial pancreas to enhance patient outcomes through localized and controlled insulin production.
Basic Stats
The share price of PharmaCyte Biotech, Inc. as of September 5, 2025 is $0.94 / share. This is a decrease of -2.95% from the prior week. The market cap (or net worth) of PharmaCyte Biotech, Inc. as of September 5, 2025 is $6.40 MM.
The Factor Analysis chart (below right) shows a view of PharmaCyte Biotech, Inc. from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | 6.40 MM |
| EV | -8.78 MM |
| Shares Out. | 6.80 MM |
| Earnings Date | |
| EPS (TTM) | 4.51 |
| Dividend Yield | |
| Ex-Dividend Date | |
| Borrow Rate | 1.29 |
| Short Shares Avail. | 0.20 MM |
| Short Interest | 0.01 MM |
| Short Float | 0.19 % |
| Days to Cover | 0.21 days |
| Risk Free Rate | 4.22 % |
| Price Change (1 yr) | -38.49 % |
| Volatility (1 yr) | 0.66 |
| Beta | 0.83 |
| Sharpe Ratio (1 yr) | -0.65 |
| Sortino Ratio (1 yr) | -1.01 |
| PE Ratio | 0.21 |
| Price/Book | 0.12 |
| Price/TBV | 0.13 |
| Book/Market | 8.11 |
| EBIT/EV | -3.49 |
| EBIT(3yr avg)/EV | -1.96 |
| ROA | 0.44 |
| ROE | 0.58 |
| ROIC | 0.59 |
| CROIC | -0.67 |
| OCROIC | -0.06 |
| Implied Volatility | 0.00 % |
| Put/Call OI Ratio | 0.05 |
| Growth | |
| Profitability | |
| Quality Score | |
| Value Score | |
| Momentum Score | |
| Stability (Low Vol) Score | |
| Analyst Sentiment | |
| Fund Sentiment | |
| Insider Sentiment | |
| Officer Sentiment | |
| Dividend Score | |
| QVM Score | |
| Piotroski F-SCORE |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for PharmaCyte Biotech, Inc.. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2021-11-08 | HC Wainwright & Co. | Neutral | Initiate |
